Key Takeaways AMD's Q3 revenues jumped 36% to $9.25B, with data center, client, and gaming units surpassing expectations.Partnerships with OpenAI and Oracle will expand AMD's AI data center presence using Instinct MI450 GPUs.Despite growth prospects, AMD trades at 65.15x forward earnings, suggesting potential overvaluation risk.Advanced Micro Devices, Inc. (AMD) recently reported a blowout third quarter and raised its outlook, driven by strong demand for its high-performance EPYC and other products. The com ...

EchoStar has sold another $2.6 billion in spectrum to Elon Musk’s SpaceX, giving the wireless and pay-TV company a stake of about 3% that is currently worth $11 billion. The transaction, announced Thursday along with the company’s third-quarter results, builds on a $17 billion spectrum deal between the companies last September. On the SpaceX end, it makes Musk a bigger player in the wireless business. In addition to the financials and the spectrum deal, the company announced that co-founder and chairman Ch ...

STILLWATER, Okla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- USA Rare Earth, Inc. (Nasdaq: USAR) (USAR or the Company) today announced its financial and operational results for the third quarter and nine months ended September 30, 2025. Third Quarter Highlights Business Highlights Identified a flow sheet for the Round Top development project, validated through bench- and pilot-scale testing, supporting a targeted Pre-Feasibility Study completion in the second half of 2026.Stillwater, Oklahoma magnet facility remain ...

Results reported for Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis. Company plans to meet with the FDA to determine path forward for efzofitimod in pulmonary sarcoidosis in the first quarter of 2026.  Company expects to complete enrollment in Phase 2 EFZO-CONNECT™ study of efzofitimod in systemic sclerosis-related interstitial lung disease (SSc-ILD) in the first half of 2026. Ended the third quarter 2025 with $92.9 million in cash, cash equivalents, restricted cash and investments. SAN DIE ...

Third quarter 2025 total revenue was $10.5 million, up 9% from prior yearAchieves five consecutive quarters of year-over-year revenue growthCompany reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the thi ...

First-in-human data from Phase 1 trial of MZE782 support best- and first-in-class potential; two Phase 2 proof-of-concept trials in phenylketonuria (PKU) and chronic kidney disease (CKD) expected to initiate in 2026 Enrollment ongoing in Phase 2 HORIZON trial of MZE829 in broad APOL1-mediated kidney disease (AMKD); topline data for initial patients expected by the end of Q1 2026 Strong balance sheet with $383.9 million in cash, cash equivalents and marketable securities following oversubscribed private plac ...

$1 trillion or must walks. Is that really what's on the line this evening. No, frankly, you know, the structure of the proposed package is complicated.It is a ten year proposal split into two tranches. And all told, the total compensation would be $1 trillion in dollar value. Right.But actually, what it is set against is a series of both operational and financial milestones. The operational ones are easy to understand. Musk has to deliver 20 million vehicles to customers, build a million robots, scale robot ...

Results for the Quarter Ended September 30, 2025 and Other Recent Highlights: Net investment income per share for the quarter was $0.38, compared to $0.39 for the quarter ended June 30, 2025Net asset value per share as of the end of the quarter was $14.66, compared to $14.75 as of June 30, 2025, a decrease of 0.6%New investment commitments made during the quarter totaled $138 million(1)Gross fundings, excluding revolver fundings,(2) totaled $142 million for the quarterThe Company received a net repayment of ...

Reports Revenue of $313.3 Million, Reflecting 9.3% GrowthRaises Full Year Guidance to Reflect Continued Strength in Member EngagementSelling Season Yields Over 80 New Clients, 900,000 New Lives, and Near 100% Retention of Existing BaseRecord $156.0 Million in Operating Cash Flow Generated over the First Nine Months of 2025Board Authorizes Up to $200 Million in Share Repurchase Program NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”), a global leader in wo ...

Third quarter revenue of $13.1 million, representing 98% growth YoY  Raising full year 2025 revenue guidance to $49 million - $50 million CARLSBAD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the third quarter ended September 30, 2025.  "We delivered another strong quarter with 98% revenue growth year-over-year, expanded gros ...